HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mather, S. J. Articles by Watson, S. A. Search for Related Content PubMed PubMed Citation Articles by Mather, S. J. Articles by Watson, S. A.

Selection of Radiolabeled Gastrin Analogs for Peptide Receptor–Targeted Radionuclide Therapy

¹ Department of Nuclear Medicine, St. Bartholomew's Hospital, London, United Kingdom; and ² Academic Unit of Cancer Studies, University of Nottingham, Nottingham, United Kingdom

Correspondence: For correspondence or reprints contact: Stephen J. Mather, PhD, Department of Nuclear Medicine, St. Bartholomew's Hospital, London, EC1A 7BE, United Kingdom. E-mail: stephen.mather{at}cancer.org.uk

The gastrin/cholecystokinin-2 (CCK-2) receptor has been identified as a possible target for peptide receptor radionuclide imaging and therapy. Several radiolabeled peptides binding to this receptor have been explored in animal models and clinical trials but either low tumor uptake or high renal retention has been found. The aim of this study was to identify a peptide with improved tumor-to-kidney pharmacodynamics when compared with current candidates. Methods: A small peptide-chelator library of 34 compounds based on the C-terminal sequences of CCK-8 or minigastrin was constructed. The peptides were radiolabeled with ¹¹¹In with high labeling efficiency (>90%), as determined by high-performance liquid chromatographic analysis. The labeled peptides were screened by assessing tumor and kidney uptake in pancreatic xenograft nude mouse models, including AR42J. An extensive biodistribution analysis was performed on the lead candidate from the library. Results: Minigastrin analogs containing a pentaglutamate sequence showed the highest tumor uptake but very high renal retention. CCK analogs showed the lowest tumor and renal uptake. Deletion of the pentaglutamate sequence in the gastrin analogs lowered the tumor uptake by a factor of 3 but decreased the kidney uptake by a factor of 20. Insertion of histidine residues in the sequence reduced kidney uptake by a further factor of almost 2-fold. In AR42J tumor-bearing mice, the peptide with the sequence DOTA-HHEAYGWMDF-NH₂ (DOTA is tetraazacyclododecane tetraacetic acid) showed the highest tumor-to-kidney ratio of all peptides studied, with saturable uptake in target organs and low uptake by nontarget tissues other than the kidney. Conclusion: This peptide is a worthwhile candidate for clinical studies to determine whether it is suitable for use in peptide receptor–targeted radionuclide therapy.

COPYRIGHT © 2006 by the Society of Nuclear Medicine, Inc.

This article has been cited by other articles:

				R. King, M. B.-U. Surfraz, C. Finucane, S. C.G. Biagini, P. J. Blower, and S. J. Mather 99mTc-HYNIC-Gastrin Peptides: Assisted Coordination of 99mTc by Amino Acid Side Chains Results in Improved Performance Both In Vitro and In Vivo J. Nucl. Med., April 1, 2009; 50(4): 591 - 598. [Abstract] [Full Text] [PDF]

				S. J. DeNardo, R. Liu, H. Albrecht, A. Natarajan, J. L. Sutcliffe, C. Anderson, L. Peng, R. Ferdani, S. R. Cherry, and K. S. Lam 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies J. Nucl. Med., April 1, 2009; 50(4): 625 - 634. [Abstract] [Full Text] [PDF]

				L. T. Littleton, B. B. Fileta, R. Massey, and T. I. Wood Kinevac Stability After Reconstitution with Sodium Chloride Injection USP, 0.9% J. Nucl. Med. Technol., March 1, 2009; 37(1): 57 - 59. [Abstract] [Full Text] [PDF]